Wellington Management Group
ELVN icon

Wellington Management Group’s Enliven Therapeutics ELVN Stock Holding History

Wellington Management Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.76M Sell
133,143
-16,983
-11% -$721K ﹤0.01% 1396
2026
Q1 		$5.88M Buy
150,126
+20,250
+16% +$561K ﹤0.01% 1376
2025
Q4 		$2M Buy
129,876
+21,316
+20% +$425K ﹤0.01% 1603
2025
Q3 		$2.22M Buy
108,560
+14,548
+15% +$293K ﹤0.01% 1605
2025
Q2 		$1.89M Buy
94,012
+9,312
+11% +$176K ﹤0.01% 1591
2025
Q1 		$1.67M Buy
84,700
+3,784
+5% +$81.4K ﹤0.01% 1596
2024
Q4 		$1.82M Buy
80,916
+10,746
+15% +$279K ﹤0.01% 1588
2024
Q3 		$1.79M Buy
70,170
+36,267
+107% +$840K ﹤0.01% 1568
2024
Q2 		$792K Buy
+33,903
New +$714K ﹤0.01% 1719

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Wellington Management Group's ELVN Position: Q2 2026 in Review

Wellington Management Group reduced its Enliven Therapeutics (ELVN) stake by 11% in Q2 2026, selling an estimated $721K and leaving 133,143 shares worth $6.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1396.

Wellington Management Group first reported a position in ELVN in Q2 2024 and has held it in 9 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Wellington Management Group held 133,143 shares of Enliven Therapeutics worth $6.76M as of Q2 2026.
  • Wellington Management Group sold 16,983 Enliven Therapeutics shares in Q2 2026, an estimated $721K.
  • Enliven Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1396 holding.
  • Wellington Management Group first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.